Pharsight

Nexplanon patents expiration

NEXPLANON's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8888745 ORGANON Applicator for inserting an implant
Aug, 2026

(2 years from now)

US10821277 ORGANON Kit for and method of assembling an applicator for inserting an implant
May, 2027

(3 years from now)

US8722037 ORGANON X-ray visible drug delivery device
Sep, 2027

(3 years from now)

US9757552 ORGANON Applicator for inserting an implant
Jul, 2030

(6 years from now)

Nexplanon is owned by Organon.

Nexplanon contains Etonogestrel.

Nexplanon has a total of 4 drug patents out of which 0 drug patents have expired.

Nexplanon was authorised for market use on 17 July, 2006.

Nexplanon is available in implant;implantation dosage forms.

Nexplanon can be used as prevention of pregnancy.

The generics of Nexplanon are possible to be released after 28 July, 2030.

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 31, 2014

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ETONOGESTREL ingredient

Market Authorisation Date: 17 July, 2006

Treatment: Prevention of pregnancy

Dosage: IMPLANT;IMPLANTATION

More Information on Dosage

NEXPLANON family patents

Family Patents